Mounjaro expanded to include weight management, providing a new treatment option for obesity and weight-related issues. This expansion enhances its role beyond diabetes care, offering comprehensive benefits for weight control.
TGA Approves Mounjaro for Weight Management in Australia
The Therapeutic Goods Administration (TGA) has officially approved tirzepatide, marketed under the brand name Mounjaro, for the treatment of overweight and obesity in individuals with comorbidities. This decision now enables General Practitioners (GPs) to prescribe Mounjaro via private prescription to eligible patients seeking effective weight management options.
Mounjaro: From Diabetes Treatment to Weight Management
Previously, Mounjaro was indicated solely for the treatment of type 2 diabetes in adults whose condition was insufficiently controlled by diet and exercise. However, the TGA’s latest decision has expanded its use to include weight management. It can now be prescribed as an adjunct to a reduced-calorie diet and increased physical activity for adults who need assistance in losing and maintaining weight.
Who Is Eligible for Mounjaro?
Mounjaro is eligible for use in adults who have:
- A Body Mass Index (BMI) of ≥30 kg/m², or
- A BMI of ≥27 kg/m² with at least one weight-related comorbid condition, such as hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or type 2 diabetes.
New Mounjaro KwikPen Delivery System
Due to global shortages of the tirzepatide injection vials, Eli Lilly Australia has introduced the Mounjaro KwikPen, a multi-use delivery system, to meet increasing demand. This change is part of a broader effort to ensure consistent supply as demand for weight-loss medications continues to rise. The company aims to replenish all doses of the KwikPen throughout Australia.
The Role of Multidisciplinary Care
According to Dr. Gary Deed, Chair of RACGP Specific Interests Diabetes, while Mounjaro provides an essential tool for weight management, it should be used as part of a multidisciplinary approach. This includes lifestyle modifications and consultations with dietitians, psychologists, and exercise physiologists. GPs play a crucial role in guiding patients through the treatment process.
Pricing and Availability
Mounjaro is currently available through private prescriptions, with prices starting at approximately $395 per month for the initial dose. While the price may seem high, it remains an important option for patients seeking long-term health improvements.
Future Outlook: PBS Reimbursement
Mounjaro is expected to be reconsidered for Pharmaceutical Benefits Scheme (PBS) reimbursement for type 2 diabetes treatment in November. If approved, this could significantly reduce costs for patients and make the medication more widely accessible.
